INVESTORS & MEDIA
News Release
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
"It is extremely satisfying for Regeneron to be recognized by Science as one of the best places to be a scientist," said
Details of the rankings and survey results will be published online on
Regeneron, founded in 1988, currently has approximately 1,670 employees, of whom more than 300 hold Ph.D. or M.D. degrees. Regeneron has added about 1,000 employees since 2007, primarily to support its research and development programs. The Company proprietary VelociGene® and VelocImmune® technologies were used to discover and develop eight fully-human monoclonal antibodies that are in clinical development. The Company's Trap fusion protein technology was applied to develop ARCALYST® (rilonacept) and two product candidates that have completed Phase 3 clinical studies.
About the
The Science and Science Careers' annual
According to Science, the 2011 global survey results were based on 3,784 responses from
About
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer. EYLEA is currently under review with U.S. and European regulatory authorities. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on www.regeneron.com.
Contact Information: | ||
Michael Aberman, M.D. | Peter Dworkin | |
Investor Relations | Corporate Communications | |
914.345.7799 | 914.345.7640 | |
SOURCE
News Provided by Acquire Media